Details of the Drug

General Information of Drug (ID: DMUOK4C)

Drug Name
Lisinopril
Synonyms
Acerbon; Acercomp; Alapril; Carace; Cipral; Cipril; Coric; Doneka; Hipril (TN); Inhibril; Inopril; LPR; Linopril; Linvas; Lipril; Lisinal; Lisinopril (INN); Lisinopril (anhydrous); Lisinopril anhydrous; Lisinoprilum; Lisinoprilum [Latin]; Lisipril; Lisoril; Lispril; Longes; Loril; Lysinopril; MK 521; MK 522; MK-521; Noperten; Novatec; Presiten; Prinil; Prinivil; Prinivil (TN); Sinopril; Sinopryl; Tensopril; Tensopril (TN); Tensyn; Tersif; Vivatec; Zestril; Zestril (TN)
Indication
Disease Entry ICD 11 Status REF
Chronic heart failure BD1Z Approved [1]
Hypertension BA00-BA04 Approved [2]
Myocardial infarction BA41-BA43 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [3]
High blood pressure BA00 Investigative [1]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 405.5
Logarithm of the Partition Coefficient (xlogp) -2.9
Rotatable Bond Count (rotbonds) 12
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 1.2 mL/min/kg [5]
Elimination
94% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 42 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.4092 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 1% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.89 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 97 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Cough Not Available BDKRB2 OTOA9D3W [7]
Chemical Identifiers
Formula
C21H31N3O5
IUPAC Name
(2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
Canonical SMILES
C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O
InChI
InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1
InChIKey
RLAWWYSOJDYHDC-BZSNNMDCSA-N
Cross-matching ID
PubChem CID
5362119
ChEBI ID
CHEBI:43755
CAS Number
76547-98-3
DrugBank ID
DB00722
TTD ID
D07HGR
VARIDT ID
DR00991
ACDINA ID
D00370
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin-converting enzyme (ACE) TTL69WB ACE_HUMAN Inhibitor [8]
HUMAN angiotensin-converting enzyme (ACE) TTGFNPD ACE_HUMAN Inhibitor [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Angiotensin-converting enzyme (ACE) OTDF1964 ACE_HUMAN Gene/Protein Processing [10]
Angiotensinogen (AGT) OTBZLYR3 ANGT_HUMAN Gene/Protein Processing [11]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [12]
B2 bradykinin receptor (BDKRB2) OTOA9D3W BKRB2_HUMAN Drug Response [7]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Protein Interaction/Cellular Processes [13]
HLA class I histocompatibility antigen, alpha chain G (HLA-G) OTMLK1KN HLAG_HUMAN Gene/Protein Processing [14]
Insulin-like growth factor-binding protein 1 (IGFBP1) OT6UQV2K IBP1_HUMAN Gene/Protein Processing [15]
Natriuretic peptides A (NPPA) OTMQNTNX ANF_HUMAN Gene/Protein Processing [11]
Renin (REN) OT52GZR2 RENI_HUMAN Gene/Protein Processing [16]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Chronic heart failure
ICD Disease Classification BD1Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Angiotensin-converting enzyme (ACE) DTT SLC33A1 2.62E-01 -0.01 -0.06
Peptide transporter 1 (SLC15A1) DTP PEPT1 6.91E-01 8.30E-03 7.24E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Lisinopril
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Eprosartan DM07K2I Major Increased risk of hyperkalemia by the combination of Lisinopril and Eprosartan. Hypertension [BA00-BA04] [17]
Aliskiren DM1BV7W Major Increased risk of hyperkalemia by the combination of Lisinopril and Aliskiren. Hypertension [BA00-BA04] [18]
TAK-491 DMCF6SX Major Increased risk of hyperkalemia by the combination of Lisinopril and TAK-491. Hypertension [BA00-BA04] [17]
Indapamide DMGN1PW Moderate Additive hypotensive effects by the combination of Lisinopril and Indapamide. Hypertension [BA00-BA04] [19]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Lisinopril and Trichlormethiazide. Hypertension [BA00-BA04] [19]
Telmisartan DMS3GX2 Major Increased risk of hyperkalemia by the combination of Lisinopril and Telmisartan. Hypertension [BA00-BA04] [17]
Irbesartan DMTP1DC Major Increased risk of hyperkalemia by the combination of Lisinopril and Irbesartan. Hypertension [BA00-BA04] [20]
Hydrochlorothiazide DMUSZHD Moderate Additive hypotensive effects by the combination of Lisinopril and Hydrochlorothiazide. Hypertension [BA00-BA04] [19]
⏷ Show the Full List of 8 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Lisinopril (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Lisinopril and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [21]
Sodium bicarbonate DMMU6BJ Minor Decreased absorption of Lisinopril due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [22]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Lisinopril and Repaglinide. Acute diabete complication [5A2Y] [23]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Lisinopril and Glibenclamide. Acute diabete complication [5A2Y] [23]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Lisinopril and Tolazamide. Acute diabete complication [5A2Y] [23]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Lisinopril and Nateglinide. Acute diabete complication [5A2Y] [23]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Lisinopril and Insulin-glulisine. Acute diabete complication [5A2Y] [23]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Lisinopril and Insulin-aspart. Acute diabete complication [5A2Y] [24]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Lisinopril and Glipizide. Acute diabete complication [5A2Y] [23]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Lisinopril and Isosorbide dinitrate. Anal fissure/fistula [DB50] [25]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Lisinopril and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [26]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Lisinopril and Cariprazine. Bipolar disorder [6A60] [27]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Lisinopril and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [28]
Mannitol DMSCDY9 Moderate Additive hypotensive effects by the combination of Lisinopril and Mannitol. Bronchiectasis [CA24] [19]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Lisinopril and Olopatadine. Conjunctiva disorder [9A60] [29]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Lisinopril and Drospirenone. Contraceptive management [QA21] [30]
Ardeparin DMYRX8B Moderate Increased risk of hyperkalemia by the combination of Lisinopril and Ardeparin. Coronary thrombosis [BA43] [17]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Lisinopril and Selegiline. Depression [6A70-6A7Z] [31]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Lisinopril and Isocarboxazid. Depression [6A70-6A7Z] [31]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Lisinopril and OPC-34712. Depression [6A70-6A7Z] [27]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Lisinopril and Phenelzine. Depression [6A70-6A7Z] [31]
Nitroglycerin DMQ2491 Moderate Additive hypotensive effects by the combination of Lisinopril and Nitroglycerin. Diabetic foot ulcer [BD54] [25]
SODIUM CITRATE DMHPD2Y Minor Decreased absorption of Lisinopril due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [22]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Lisinopril and Ethacrynic acid. Essential hypertension [BA00] [32]
Acetazolamide DM1AF5U Moderate Additive hypotensive effects by the combination of Lisinopril and Acetazolamide. Glaucoma [9C61] [19]
Dichlorphenamide DMH7IDQ Moderate Additive hypotensive effects by the combination of Lisinopril and Dichlorphenamide. Glaucoma [9C61] [32]
Chlorothiazide DMLHESP Moderate Additive hypotensive effects by the combination of Lisinopril and Chlorothiazide. Heart failure [BD10-BD1Z] [19]
Bumetanide DMRV7H0 Moderate Additive hypotensive effects by the combination of Lisinopril and Bumetanide. Heart failure [BD10-BD1Z] [19]
Hydroflumethiazide DMVPUQI Moderate Additive hypotensive effects by the combination of Lisinopril and Hydroflumethiazide. Heart failure [BD10-BD1Z] [19]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Lisinopril and Procarbazine. Hodgkin lymphoma [2B30] [31]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Lisinopril and Brentuximab vedotin. Hodgkin lymphoma [2B30] [33]
Didanosine DMI2QPE Minor Decreased absorption of Lisinopril due to altered gastric pH caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [22]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Lisinopril and Isosorbide mononitrate. Hydrocephalus [8D64] [25]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Lisinopril and Mipomersen. Hyper-lipoproteinaemia [5C80] [34]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Lisinopril and Teriflunomide. Hyper-lipoproteinaemia [5C80] [35]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Lisinopril and BMS-201038. Hyper-lipoproteinaemia [5C80] [36]
Potassium chloride DMMTAJC Major Increased risk of hyperkalemia by the combination of Lisinopril and Potassium chloride. Hypo-kalaemia [5C77] [37]
Tolvaptan DMIWFRL Moderate Increased risk of hyperkalemia by the combination of Lisinopril and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [38]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Lisinopril and Propiomazine. Insomnia [7A00-7A0Z] [27]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Lisinopril and ITI-007. Insomnia [7A00-7A0Z] [27]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Lisinopril and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [39]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Lisinopril and Idelalisib. Mature B-cell leukaemia [2A82] [40]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Lisinopril due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [35]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Lisinopril and Ozanimod. Multiple sclerosis [8A40] [31]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Lisinopril and Promethazine. Nausea/vomiting [MD90] [27]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Lisinopril and Polythiazide. Oedema [MG29] [19]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Lisinopril and Safinamide. Parkinsonism [8A00] [31]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Lisinopril and Rasagiline. Parkinsonism [8A00] [31]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Lisinopril and Terazosin. Prostate hyperplasia [GA90] [41]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Lisinopril and Silodosin. Prostate hyperplasia [GA90] [41]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Lisinopril and Levomepromazine. Psychotic disorder [6A20-6A25] [27]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Lisinopril and Leflunomide. Rheumatoid arthritis [FA20] [35]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Lisinopril and Quetiapine. Schizophrenia [6A20] [27]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Lisinopril and Mesoridazine. Schizophrenia [6A20] [27]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Lisinopril and Aripiprazole. Schizophrenia [6A20] [27]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Lisinopril and Iloperidone. Schizophrenia [6A20] [27]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Lisinopril and Paliperidone. Schizophrenia [6A20] [27]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Lisinopril and Perphenazine. Schizophrenia [6A20] [27]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Lisinopril and Molindone. Schizophrenia [6A20] [27]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Lisinopril and Thiothixene. Schizophrenia [6A20] [27]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Lisinopril and Trifluoperazine. Schizophrenia [6A20] [27]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Lisinopril and Risperidone. Schizophrenia [6A20] [27]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Lisinopril and Amisulpride. Schizophrenia [6A20] [27]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Lisinopril and Asenapine. Schizophrenia [6A20] [27]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Lisinopril and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [42]
Tacrolimus DMZ7XNQ Moderate Increased risk of hyperkalemia by the combination of Lisinopril and Tacrolimus. Transplant rejection [NE84] [43]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Lisinopril and Tolbutamide. Type 2 diabetes mellitus [5A11] [23]
Liraglutide DM3FXPS Minor Altered absorption of Lisinopril due to GI dynamics variation caused by Liraglutide. Type 2 diabetes mellitus [5A11] [44]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Lisinopril and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [23]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Lisinopril and Methdilazine. Vasomotor/allergic rhinitis [CA08] [27]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Lisinopril and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [45]
⏷ Show the Full List of 71 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Hydrazine yellow E00409 164825 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium hydrogenphosphate E00294 24441 Diluent
Calcium phosphate E00298 24456 Anticaking agent; Buffering agent; Desiccant; Diluent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Lisinopril 10 mg tablet 10 mg Oral Tablet Oral
Lisinopril 20 mg tablet 20 mg Oral Tablet Oral
Lisinopril 30 mg tablet 30 mg Oral Tablet Oral
Lisinopril 40 mg tablet 40 mg Oral Tablet Oral
Lisinopril 5 mg tablet 5 mg Oral Tablet Oral
Lisinopril 2.5 mg tablet 2.5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Lisinopril FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc. 2020 Apr 7;9(7):e016219.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71.
9 Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
10 Targeted catalytic inactivation of angiotensin converting enzyme by lisinopril-coupled transition-metal chelates. J Am Chem Soc. 2012 Feb 22;134(7):3396-410. doi: 10.1021/ja208791f. Epub 2012 Feb 10.
11 Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction. Br Heart J. 1993 Jun;69(6):512-5. doi: 10.1136/hrt.69.6.512.
12 Reduced bcl-2 concentrations in hypertensive patients after lisinopril or nifedipine administration. Am J Hypertens. 1999 Jan;12(1 Pt 1):73-5. doi: 10.1016/s0895-7061(98)00217-9.
13 Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Mediators Inflamm. 2008;2008:305087. doi: 10.1155/2008/305087. Epub 2008 Dec 1.
14 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
15 Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension: effects of angiotensin converting enzyme inhibition. J Hypertens. 1998 Jun;16(6):863-70. doi: 10.1097/00004872-199816060-00018.
16 Hemodynamic responses to converting enzyme inhibition in patients with renal disease. Am J Hypertens. 1989 Aug;2(8):599-603. doi: 10.1093/ajh/2.8.599.
17 Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
18 Health Canada "Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT)." .
19 Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
20 Product Information. Micardis (telmisartan). Boehringer-Ingelheim, Ridgefield, CT.
21 Cerner Multum, Inc. "Australian Product Information.".
22 Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P "Impairment of captopril bioavailability by concomitant food and antacid intake." Int J Clin Pharmacol Ther Toxicol 22 (1984): 626-9. [PMID: 6389377]
23 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
24 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
25 Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7. [PMID: 1901528]
26 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
27 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
28 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
29 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
30 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
31 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
32 Murphy BF, Whitworth JA, Kincaid-Smith P "Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics." Br Med J 288 (1984): 844-5. [PMID: 6322905]
33 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
34 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
35 Canadian Pharmacists Association.
36 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
37 Product Information. K-Dur (potassium chloride). Schering Laboratories, Kenilworth, NJ.
38 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
39 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
40 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
41 Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
42 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
43 Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
44 Product Information. Victoza (liraglutide). Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
45 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.